Cephalon's Treanda wins US approval in lymphoma
LOS ANGELES, Oct 31 (Reuters) - Cephalon Inc (CEPH.O) won U.S. approval to sell its chemotherapy drug Treanda for treatment of patients with a type of non-Hodgkin's lymphoma, the company said on Friday.
The drug was previously approved in March by the U.S. Food and Drug Administration as a treatment for chronic lymphocytic leukemia, the most common form of leukemia in the United States.
The latest approval applies to Treanda for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed despite treatment with Rituxan, or a regimen containing Rituxan, known generically as rituximab.
An estimated 30,000 people in the United States will be diagnosed this year with indolent NHL, a slow-growing cancer of the lymphatic system, according to the National Cancer Institute.
Cephalon said a pivotal trial of Treanda showed that it delays progression of the disease for more than nine months. (Reporting by Deena Beasley; editing by Carol Bishopric)
© Thomson Reuters 2009 All rights reserved
Citadel enters the fray
Kenneth Griffin's powerful hedge fund has waded into the case of Goldman Sachs' purloined computer code, suing three of its former employees for setting up Teza Technologies. Full Article | Full Coverage
